Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Gottesman

Showing results (461-470 of 602) with videos related to

Pageof 61
Sort By:
Annals of the New York Academy of Sciences|April 21, 2007
Cyclosporin A-dependent downregulation of the Na+/Ca2+ exchanger expressionH Rahamimoff, B Elbaz, A Alperovich, et al.
The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society|December 1, 1987
Immunocytochemical localization of P170 at the plasma membrane of multidrug-resistant human cellsM C Willingham, N D Richert, M M Cornwell, et al.
Cancer Research|October 22, 2009
Identification of compounds selectively killing multidrug-resistant cancer cellsDóra Türk, Matthew D Hall, Benjamin F Chu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1990
Expression of the multidrug resistance, MDR1, gene in neuroblastomasL J Goldstein, A T Fojo, K Ueda, et al.
Assay and Drug Development Technologies|June 25, 2009
A dual-fluorescence high-throughput cell line system for probing multidrug resistanceKyle R Brimacombe, Matthew D Hall, Douglas S Auld, et al.
Cancer Research|March 15, 1991
The multidrug resistance phenotype: 31P nuclear magnetic resonance characterization and 2-deoxyglucose toxicityO Kaplan, J W Jaroszewski, R Clarke, et al.
Trends in Molecular Medicine|July 15, 2018
Pluripotent Stem Cell Platforms for Drug DiscoveryKevin G Chen, Barbara S Mallon, Kyeyoon Park, et al.
Antisense & Nucleic Acid Drug Development|February 24, 2001
Targeting the human mdr1 gene by 125I-labeled triplex-forming oligonucleotidesO A Sedelnikova, I G Panyutin, A N Luu, et al.
Molecular Cancer Therapeutics|November 8, 2014
The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicityKi-Eun Chang, Bih-Rong Wei, James P Madigan, et al.
Molecular Cancer Therapeutics|September 16, 2008
Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transportersMitsunori Okabe, Gergely Szakács, Mark A Reimers, et al.
Pageof 61

Showing results (461-470 of 602) with videos related to

Sort By:
Pageof 61
Annals of the New York Academy of Sciences|April 21, 2007
Cyclosporin A-dependent downregulation of the Na+/Ca2+ exchanger expressionH Rahamimoff, B Elbaz, A Alperovich, et al.
The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society|December 1, 1987
Immunocytochemical localization of P170 at the plasma membrane of multidrug-resistant human cellsM C Willingham, N D Richert, M M Cornwell, et al.
Cancer Research|October 22, 2009
Identification of compounds selectively killing multidrug-resistant cancer cellsDóra Türk, Matthew D Hall, Benjamin F Chu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1990
Expression of the multidrug resistance, MDR1, gene in neuroblastomasL J Goldstein, A T Fojo, K Ueda, et al.
Assay and Drug Development Technologies|June 25, 2009
A dual-fluorescence high-throughput cell line system for probing multidrug resistanceKyle R Brimacombe, Matthew D Hall, Douglas S Auld, et al.
Cancer Research|March 15, 1991
The multidrug resistance phenotype: 31P nuclear magnetic resonance characterization and 2-deoxyglucose toxicityO Kaplan, J W Jaroszewski, R Clarke, et al.
Trends in Molecular Medicine|July 15, 2018
Pluripotent Stem Cell Platforms for Drug DiscoveryKevin G Chen, Barbara S Mallon, Kyeyoon Park, et al.
Antisense & Nucleic Acid Drug Development|February 24, 2001
Targeting the human mdr1 gene by 125I-labeled triplex-forming oligonucleotidesO A Sedelnikova, I G Panyutin, A N Luu, et al.
Molecular Cancer Therapeutics|November 8, 2014
The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicityKi-Eun Chang, Bih-Rong Wei, James P Madigan, et al.
Molecular Cancer Therapeutics|September 16, 2008
Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transportersMitsunori Okabe, Gergely Szakács, Mark A Reimers, et al.
Pageof 61